Vieira S A, Deininger M W, Sorour A, Sinclair P, Foroni L, Goldman J M, Melo J V
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
Genes Chromosomes Cancer. 2001 Dec;32(4):353-63. doi: 10.1002/gcc.1200.
Expression of BCR/ABL, a constitutively active tyrosine kinase, is a primary event in the pathogenesis of chronic myeloid leukemia (CML) and Ph-positive acute lymphoblastic leukemia (Ph+ALL). Inhibition of the BCR/ABL kinase activity in the BV173 CML cell line with STI571 resulted in a significant overexpression of a 10-kb novel mRNA, found to be the human ortholog of the murine Bach2, a B-cell-specific transcription factor. The human BACH2 cDNA is >9,120 bp long and includes an open reading frame of 2,526 bp encoding a protein with a basic leucine zipper (bZip) and a BTB/POZ domain, mediating DNA-binding and heterodimerization. BACH2 was consistently upregulated (2-10-fold) in all 10 Ph+ lymphoid lines tested following BCR/ABL inhibition. In CML myeloid cell lines (n = 8) and BCR/ABL-negative lines (n = 6), BACH2 was either undetectable by Northern blotting or did not change in response to STI571, suggesting that BACH2 repression by BCR/ABL may be specifically relevant to lymphoid transformation. Quantitative RT/PCR revealed a significantly lower level of BACH2 expression in leukocytes from patients with CML (n = 24) as compared to normal individuals (n = 23) (P < 0.0005). Moreover, CD34+ cells treated in vitro with STI571 exhibited a consistent upregulation of BACH2 in 8 of 10 CMLs but in none of the 9 normal individuals tested. Transcription regulation of BACH2 in BCR/ABL-positive cells was exerted via the MEK pathways, as shown by their responses to the U0126-specific inhibitor. Radiation hybrid mapping and FISH revealed that BACH2 is located on chromosome 6, band q15, a region frequently associated with deletions in ALL and non-Hodgkin's lymphoma, suggesting its possible role as a tumor suppressor gene. However, no rearrangement or loss of signal was observed by Southern blotting in 34 lymphomas, 10 B-cell ALLs, or seven reactive lymph nodes. The pattern of BACH2 expression in BCR/ABL-positive cells suggests that transcriptional repression by this regulator is impaired in CML and may contribute to the emergence of lymphoid blast crisis.
组成型活性酪氨酸激酶BCR/ABL的表达是慢性髓性白血病(CML)和Ph阳性急性淋巴细胞白血病(Ph+ALL)发病机制中的主要事件。用STI571抑制BV173 CML细胞系中的BCR/ABL激酶活性导致一种10kb新mRNA的显著过表达,该mRNA被发现是小鼠Bach2(一种B细胞特异性转录因子)的人类同源物。人类BACH2 cDNA长度超过9120bp,包含一个2526bp的开放阅读框,编码一种具有碱性亮氨酸拉链(bZip)和BTB/POZ结构域的蛋白质,介导DNA结合和异二聚化。在所有10个经测试的Ph+淋巴细胞系中,BCR/ABL抑制后BACH2持续上调(2 - 10倍)。在CML髓细胞系(n = 8)和BCR/ABL阴性细胞系(n = 6)中,通过Northern印迹法检测不到BACH2,或者其表达对STI571无变化,这表明BCR/ABL对BACH2的抑制可能与淋巴细胞转化特别相关。定量RT/PCR显示,与正常个体(n = 23)相比,CML患者(n = 24)白细胞中BACH2的表达水平显著降低(P < 0.0005)。此外,在体外经STI571处理的CD34+细胞中,10例CML中有8例BACH2持续上调,但在9例测试正常个体中均未出现上调。如对U0126特异性抑制剂的反应所示,BCR/ABL阳性细胞中BACH2的转录调节是通过MEK途径进行的。辐射杂种图谱分析和荧光原位杂交显示,BACH2位于6号染色体q15带,该区域常与ALL和非霍奇金淋巴瘤的缺失相关,提示其可能作为肿瘤抑制基因发挥作用。然而,在34例淋巴瘤、10例B细胞ALL或7个反应性淋巴结中,通过Southern印迹法未观察到重排或信号缺失。BCR/ABL阳性细胞中BACH2的表达模式表明,该调节因子的转录抑制在CML中受损,可能导致淋巴母细胞危象的出现。